- This hub offers educational resources designed to support understanding and interpretation of BBBM tests in neurology. These materials complement—but do not replace—clinical training and guidelines.
- Access expert insights from leading KOLs on emerging research, clinical applications, and best practices in neurological diagnostics.
- Explore case studies and practical guidance to strengthen diagnostic confidence and optimise patient outcomes.
Expert insights
Ashton Harper
Ashton Harper (Global Medical Affairs Lead - Neuroscience, Roche Diagnostics) shares how earlier, accurate dementia diagnoses could reduce diagnostic uncertainty, and the impact this could have for healthcare professionals and patients.
Case Studies
Accelerating Alzheimer's Diagnosis: CSF Testing in Greater Manchester
Discover how Greater Manchester Mental Health NHS Foundation Trust and Manchester University NHS Foundation Trust transformed the Alzheimer's diagnostic pathway through local CSF biomarker testing.
In this case study:
- Reduced time to results from up to 14 weeks to as little as 2 weeks
- Earlier diagnosis, up to 5 years sooner, while patients retain capacity for planning
- Streamlined sample collection and storage with Elecsys CSF assays
- Improved patient outcomes through faster access to post-diagnostic support and clinical trials
- Practical insights on setting up a lumbar puncture service and local testing pathway
Speak to your Roche representative about implementing CSF testing in your trust
Case Study Download
Our Director of Access and Innovation, Matthew Johnson, outlines exactly why England needs an ambitious Modern Service Framework for Dementia and Frailty and why action must not be delayed.
Our Director of Access and Innovation, Matthew Johnson, outlines exactly why England needs an ambitious Modern Service Framework for Dementia and Frailty and why action must not be delayed.
Despite how much early diagnosis matters, too many people are still waiting too long for answers. Hear about Pat's story and how addvances in biomarker testing and diagnostic innovation are providing new ways to detect and understand Alzheimer's disease earlier and more accurately than ever before.
Despite how much early diagnosis matters, too many people are still waiting too long for answers. Hear about Pat's story and how addvances in biomarker testing and diagnostic innovation are providing new ways to detect and understand Alzheimer's disease earlier and more accurately than ever before.
This article explores how blood-based biomarker tests can be a breakthrough for Alzheimer's diagnosis, helping to enable more effective treatment while reducing overarching healthcare costs.
This article explores how blood-based biomarker tests can be a breakthrough for Alzheimer's diagnosis, helping to enable more effective treatment while reducing overarching healthcare costs.
